Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | PIP4K2A | P48426 | 5/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272079 | 0.88 | SYK (0.70) | SYKAURKATNIKNPC1RAB9A | |
| SCHEMBL10272206 | 0.87 | SYK (0.48) | SYKAURKATNIKNPC1RAB9A | |
| SCHEMBL2716777 | 0.85 | PIP4K2A (0.48) | SYKAURKAPIP4K2A | |
| SCHEMBL2716765 | 0.85 | PIP4K2A (0.48) | SYKAURKAPIP4K2A | |
| SCHEMBL10272082 | 0.83 | SYK (0.43) | SYKAURKAPIP4K2A | |
| SCHEMBL2715096 | 0.78 | SYK (0.61) | SYKAURKAPIP4K2ANPC1RAB9A | |
| SCHEMBL9107210 | 0.78 | SYK (0.61) | SYKAURKAPIP4K2ANPC1RAB9A | |
| SCHEMBL1354375 | 0.78 | SYK (1.00) | SYK | |
| SCHEMBL16743177 | 0.78 | SYK (0.74) | SYKAURKATNIKBTK | |
| SCHEMBL1354369 | 0.78 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012061415-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |